2BBBullish & Bearish
Alnylam Pharmaceuticals, Inc. (ALNY) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 61 out of 100.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Alnylam Pharmaceuticals, Inc.’s current 2BB score is 61 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 67 | High |
| Momentum | 44 | Stable |
| Financial strength | 70 | Strong |
| Quality | 97 | Very Strong |
| Risk | 30 | Low |
| Founded | Jun 14, 2002 |
| Employees | 2.5K |
| P/E ratio | 38.20 |
| 52-week range | $197.81 – $495.55 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-10 | — | 1.9223 | — | $1.60B |
| 2026-10-29 | — | 1.7793 | — | $1.47B |
| 2026-07-30 | — | 1.6075 | — | $1.35B |
| 2026-04-30 | 1.51 | 0.9648 | $1.17B | $1.14B |